Drugs / INO-3106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02241369 | May 2014 → Sep 2018 | preneoplastic lesion | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-02-03 | Inovio Pharmaceuticals | Results Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections inovio.com ↗
Study results demonstrated that INO-3106 generated immunogenicity and engagement and expansion of an HPV 6-specific cellular response, including cytotoxic T cells. |
| 2019-04-03 | Inovio Pharmaceuticals | Results Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-03 | Inovio Pharmaceuticals | Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections inovio.com ↗ |
| 2019-04-03 | Inovio Pharmaceuticals | Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-3106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02241369 ↗ |
| Modality | Vaccine | “INO-3106 alone or in combination with INO-9012 DNA vaccines” NCT02241369 ↗ |
| Route | Other | “delivered by Electroporation” NCT02241369 ↗ |